BioCapital
Filter News
Found 39,540 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Danaher Schedules Third Quarter 2021 Earnings Conference Call
9/21/2021
Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
-
The company's focus is to find somebody with considerable pharmaceutical industry experience to help advance regulatory and commercialization initiatives for leronlimab.
-
The FDA approved Kimmtrak for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (mUM).
-
Incyte's decision follows consultation with the FDA, where it decided that it could not support any confirmatory studies that might be required in the future given the limited time frame.
-
Cystic Fibrosis Foundation Announces Steven Rowe, MD, as Next Chief Scientific Officer
1/26/2022
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies.
-
Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
1/26/2022
Immunocore Holdings plc today announces approval from the United States Food and Drug Administration (FDA) of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).
-
Melanoma Research Alliance Statement on FDA Approval of Tebentafusp, the First Drug for Treating Metastatic Uveal Melanoma
1/26/2022
The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Marc Hurlbert, PhD and MRA President & CEO Michael Kaplan on the Food & Drug Administration approval of tebentafusp, the first drug for treating metastatic uveal melanoma.
-
CLX Health Acquires SymCheck® to Enhance Automated Health Screening
1/26/2022
CLX Health, a leading developer of cloud-based solutions for managing the COVID-19 testing ecosystem with their TrustAssure™ Global Network, today announced it acquired SymCheck®, an automated mobile health screening, assessment and compliance software platform.
-
University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
1/26/2022
Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 "Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer."
-
The Multicancer Early Detection (MCED) Consortium announces new leadership
1/26/2022
Today, the Multicancer Early Detection (MCED) Consortium, an independent nonprofit organization dedicated to evaluating the clinical and public health value of MCED tests in earlier cancer detection and treatment, announced the appointment of Michelle Le Beau, Ph.D. as chair and Larry Kessler, Sc.D., as deputy chair.
-
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome
1/26/2022
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with OrphanDC.
-
Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022
1/26/2022
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that the Company will be presenting at the B. Riley Securities Oncology Conference being held virtually on January 27-28, 2022.
-
BioSpace sat down with Niko Andre, M.D., Ph.D., global franchise head for hematology and immuno-oncology at AstraZeneca.
-
Maxim Biomedical Inc. Receives EUA for New ClearDetect™ COVID-19 Antigen Home Test
1/25/2022
On January 19, 2022 , Maxim Biomedical (MaximBio) received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for their new ClearDetect™ COVID-19 Antigen Home Test ( ClearDetect™ ).
-
Large Study Provides Reassurance that COVID-19 Vaccination Does Not Affect Fertility or Early Pregnancy
1/25/2022
Vaccination against COVID-19 did not affect fertility outcomes in patients undergoing in-vitro fertilization (IVF), a new study has found.
-
Cartesian Therapeutics Doses Patient with First Allogeneic RNA Cell Therapy for Multiple Myeloma
1/25/2022
Cartesian Therapeutics today announced that it has dosed the first patient in a Phase 1/2a multicenter clinical study evaluating Descartes-25 in patients with multiple myeloma.
-
Incyte Provides Update on Parsaclisib and MCLA-145
1/25/2022
Incyte (Nasdaq:INCY) today announced updates regarding the clinical development of parsaclisib, the Company’s next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), and MCLA-145, its CD137/PD-L1 bispecific antibody co-developed under a global collaboration and license agreement with Merus.
-
Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury
1/25/2022
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration), today announced that Chinese researchers confirmed the ability of Thymosin beta 4 (Tβ4) to protect corneal stromal cells from damage due to ethanol exposure and significantly promote wound healing.
-
PGDx Announces an Updated Medicare Reimbursement Rate for the elio™ tissue complete Test
1/25/2022
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced an update to the Proprietary Laboratory Analyses (PLA) code for its comprehensive genomic profiling test, PGDx elio™ tissue complete.